GBI Research, Feb 2012, Pages: 290
covered in the report, as are immunomodulators R&D pipelines. The report provides in-depth analysis and market forecasts of the major drug classes, which include immunosuppressants (antibodies, interferon
Business Insights, Aug 2011, Pages: 159
are the new therapeutic approaches in the immunomodulators market and which of these offer significant potential in the future?
- What is the forecast commercial potential of the most promising compounds
GlobalData, Dec 2011, Pages: 79
Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Crohn’s Disease (CD
GlobalData, March 2011, Pages: 81
Diabetic Retinopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Diabetic Retinopathy
GlobalData, Sep 2011, Pages: 83
Ulcerative Colitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Ulcerative Colitis
GlobalData, July 2011, Pages: 74
key markets. Pipeline candidates fall under major therapeutic classes such as Tyrosine kinases inhibitor, VEGF inhibitor, Immunomodulators.
- Analysis of the current and future competition in the seven
GlobalData, March 2011, Pages: 80
key markets. Pipeline candidates fall under major therapeutic classes such as Anti-CD20 Mab, Bcl-2 Inhibitors, CDK Inhibitors, Multi TKIs, Immunomodulators, Phosphodiesterase Inhibitors, HDAC Inhibitors
GlobalData, March 2011, Pages: 60
Lupus Nephritis Therapeutics - Pipeline Assessment and Market Forecast to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Lupus Nephritis Therapeutics
GlobalData, March 2011, Pages: 61
Liver Cirrhosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Liver Cirrhosis Therapeutics
Medpredict, March 2010, Pages: 120
In this last Gastroenterology Thought Leader Panel the publisher reported on key unmet needs in the treatment of Crohn’s disease and ulcerative colitis. In this report the publisher asks six
GlobalData, Sep 2011, Pages: 89
being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as immunomodulators, NMDA receptor antagonists, platelet inhibitor, polyketide
GlobalData, Oct 2011, Pages: 84
Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Systemic
GlobalData, Sep 2010, Pages: 38
pipeline with more emerging therapies. Globally, the US remains the largest market for atopic dermatitis therapeutics, and was valued at $415m in 2009.However, with most of the demand expected to come from
Medpredict, Sep 2011, Pages: 158
exercise with them. The purpose was to designate their “fantasy formulary”, comprised of the top seven therapeutics, currently in the development pipeline, that they want to see available for use
Medpredict, June 2010, Pages: 134
exercise with us. The purpose was to designate their “fantasy formulary,” comprised of the top seven therapeutics, currently in the development pipeline, which they want to see available for use
